-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
There -X- _ O
is -X- _ O
an -X- _ O
urgent -X- _ O
need -X- _ O
to -X- _ O
develop -X- _ O
new -X- _ O
innovative -X- _ O
therapies -X- _ O
for -X- _ O
the -X- _ O
control -X- _ O
of -X- _ O
advanced -X- _ O
cancer. -X- _ O
The -X- _ O
combination -X- _ O
of -X- _ O
antigen-specific -X- _ O
immunotherapy -X- _ O
with -X- _ O
the -X- _ O
employment -X- _ O
of -X- _ O
immunomodulatory -X- _ O
agents -X- _ O
has -X- _ O
emerged -X- _ O
as -X- _ O
a -X- _ O
potentially -X- _ O
plausible -X- _ O
approach -X- _ O
for -X- _ O
the -X- _ O
control -X- _ O
of -X- _ O
advanced -X- _ O
cancer. -X- _ O
METHODS -X- _ O
: -X- _ O
In -X- _ O
the -X- _ O
current -X- _ O
study -X- _ O
, -X- _ O
we -X- _ O
explored -X- _ O
the -X- _ O
combination -X- _ O
of -X- _ O
the -X- _ O
DNA -X- _ B-Intervention
vaccine -X- _ I-Intervention
encoding -X- _ I-Intervention
calreticulin -X- _ I-Intervention
( -X- _ I-Intervention
CRT -X- _ I-Intervention
) -X- _ I-Intervention
linked -X- _ I-Intervention
to -X- _ I-Intervention
human -X- _ I-Intervention
papillomavirus -X- _ I-Intervention
type -X- _ I-Intervention
16 -X- _ I-Intervention
( -X- _ I-Intervention
HPV-16 -X- _ I-Intervention
) -X- _ I-Intervention
E7 -X- _ I-Intervention
antigen -X- _ I-Intervention
( -X- _ I-Intervention
CRT -X- _ I-Intervention
/ -X- _ I-Intervention
E7 -X- _ I-Intervention
) -X- _ I-Intervention
with -X- _ I-Intervention
the -X- _ I-Intervention
TLR7 -X- _ I-Intervention
agonist -X- _ I-Intervention
imiquimod -X- _ I-Intervention
for -X- _ O
their -X- _ O
ability -X- _ O
to -X- _ O
generate -X- _ O
E7-specific -X- _ B-Outcome
immune -X- _ I-Outcome
responses -X- _ I-Outcome
and -X- _ I-Outcome
antitumor -X- _ I-Outcome
effects -X- _ I-Outcome
in -X- _ O
tumor-bearing -X- _ B-Patient
mice. -X- _ I-Patient
RESULTS -X- _ O
: -X- _ O
We -X- _ O
observed -X- _ O
that -X- _ O
treatment -X- _ B-Outcome
with -X- _ I-Outcome
CRT -X- _ I-Outcome
/ -X- _ I-Outcome
E7 -X- _ I-Outcome
DNA -X- _ I-Outcome
in -X- _ I-Outcome
combination -X- _ I-Outcome
with -X- _ I-Outcome
imiquimod -X- _ I-Outcome
leads -X- _ I-Outcome
to -X- _ I-Outcome
an -X- _ I-Outcome
enhancement -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
E7-specific -X- _ I-Outcome
CD8+ -X- _ I-Outcome
T -X- _ I-Outcome
cell -X- _ I-Outcome
immune -X- _ I-Outcome
responses -X- _ I-Outcome
and -X- _ I-Outcome
a -X- _ I-Outcome
decrease -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
number -X- _ I-Outcome
of -X- _ I-Outcome
myeloid-derived -X- _ I-Outcome
suppressor -X- _ I-Outcome
cells -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
tumor -X- _ I-Outcome
microenvironment -X- _ I-Outcome
of -X- _ I-Outcome
tumor-bearing -X- _ I-Outcome
mice. -X- _ I-Outcome
Furthermore -X- _ O
, -X- _ O
treatment -X- _ B-Outcome
with -X- _ I-Outcome
CRT -X- _ I-Outcome
/ -X- _ I-Outcome
E7 -X- _ I-Outcome
DNA -X- _ I-Outcome
in -X- _ I-Outcome
combination -X- _ I-Outcome
with -X- _ I-Outcome
imiquimod -X- _ I-Outcome
leads -X- _ I-Outcome
to -X- _ I-Outcome
significantly -X- _ I-Outcome
improved -X- _ I-Outcome
antitumor -X- _ I-Outcome
effects -X- _ I-Outcome
and -X- _ I-Outcome
prolonged -X- _ I-Outcome
survival -X- _ I-Outcome
in -X- _ I-Outcome
treated -X- _ I-Outcome
mice. -X- _ I-Outcome
In -X- _ O
addition -X- _ O
, -X- _ O
treatment -X- _ B-Outcome
with -X- _ I-Outcome
imiquimod -X- _ I-Outcome
led -X- _ I-Outcome
to -X- _ I-Outcome
increased -X- _ I-Outcome
number -X- _ I-Outcome
of -X- _ I-Outcome
NK1.1+ -X- _ I-Outcome
cells -X- _ I-Outcome
and -X- _ I-Outcome
F4 -X- _ I-Outcome
/ -X- _ I-Outcome
80+ -X- _ I-Outcome
cells -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
tumor -X- _ I-Outcome
microenvironment. -X- _ I-Outcome
Macrophages -X- _ I-Outcome
and -X- _ I-Outcome
NK1.1+ -X- _ I-Outcome
cells -X- _ I-Outcome
were -X- _ I-Outcome
found -X- _ I-Outcome
to -X- _ I-Outcome
play -X- _ I-Outcome
an -X- _ I-Outcome
important -X- _ I-Outcome
role -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
antitumor -X- _ I-Outcome
effects -X- _ I-Outcome
mediated -X- _ I-Outcome
by -X- _ I-Outcome
treatment -X- _ I-Outcome
with -X- _ I-Outcome
CRT -X- _ I-Outcome
/ -X- _ I-Outcome
E7 -X- _ I-Outcome
DNA -X- _ I-Outcome
in -X- _ I-Outcome
combination -X- _ I-Outcome
with -X- _ I-Outcome
imiquimod. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
Thus -X- _ O
, -X- _ O
our -X- _ O
data -X- _ O
suggests -X- _ O
that -X- _ O
the -X- _ O
combination -X- _ B-Outcome
of -X- _ I-Outcome
therapeutic -X- _ I-Outcome
HPV -X- _ I-Outcome
DNA -X- _ I-Outcome
vaccination -X- _ I-Outcome
with -X- _ I-Outcome
topical -X- _ I-Outcome
treatment -X- _ I-Outcome
with -X- _ I-Outcome
the -X- _ I-Outcome
TLR7 -X- _ I-Outcome
agonist -X- _ I-Outcome
imiquimod -X- _ I-Outcome
enhances -X- _ I-Outcome
the -X- _ I-Outcome
antitumor -X- _ I-Outcome
immunity -X- _ I-Outcome
induced -X- _ I-Outcome
by -X- _ I-Outcome
DNA -X- _ I-Outcome
vaccination. -X- _ I-Outcome
The -X- _ O
current -X- _ O
study -X- _ O
has -X- _ O
significant -X- _ O
implications -X- _ O
for -X- _ O
future -X- _ O
clinical -X- _ O
translation -X- _ O
. -X- _ O

